SynthesisArchives of disease in childhood2004
Systematic review of the dose-response relation of inhaled fluticasone propionate.
Synthesis in Archives of disease in childhood, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?The AAPS journal · 2021Trial
- Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.The Journal of allergy and clinical immunology · 2015Trial
- Mechanistic Physiologically Based Pharmacokinetic Modeling of Dry Powder and Nebulized Formulations of Orally Inhaled TMEM16A Potentiator GDC-6988.CPT: pharmacometrics & systems pharmacology · 2025Article
- Dangers of under-treatment and over-treatment with inhaled corticosteroids in children with asthma.Pediatric pulmonology · 2025Article
- START CARE: a protocol for a randomised controlled trial of step-wise budesonide-formoterol reliever-based treatment in children.ERJ open research · 2024Article
- Unmet needs in asthma.Therapeutics and clinical risk management · 2019Review
- Pharmacotherapy of critical asthma syndrome: current and emerging therapies.Clinical reviews in allergy & immunology · 2015Review
- International consensus on (ICON) pediatric asthma.Allergy · 2012Article
- Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone proprionate.International journal of pediatric endocrinology · 2010Article
- Management of asthma in children.BMJ (Clinical research ed.) · 2007Review
- Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations.Paediatric drugs · 2007Review
- Very high dose inhaled corticosteroids: panacea or poison?Archives of disease in childhood · 2006Review
- Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone.Archives of disease in childhood · 2006Article
- Inhaled fluticasone reduces bronchial responsiveness and airway inflammation in cats with mild chronic bronchitis.Journal of feline medicine and surgery · 2006Article
- The dose-response relationship of inhaled corticosteroids in asthma.Current allergy and asthma reports · 2004Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo examine the dose-response relation of inhaled fluticasone for both efficacy and adrenal function in children with asthma.
methodsSystematic review of double blind randomised dose-response studies of fluticasone in children of at least 4 weeks duration.
main outcome measuresFEV1, morning peak expiratory flow, night awakenings, beta agonist use, major exacerbations, 12 or 24 hour urinary cortisol, peak plasma cortisol post-stimulation.
resultsSeven studies of 1733 children with asthma met the inclusion criteria for efficacy. The dose-response curve for each efficacy outcome measure suggested that the response began to plateau between 100 and 200 microg per day with additional efficacy at the 400 microg per day dose shown in one study of severe asthmatics. Five studies of 1096 children with asthma met the inclusion criteria for assessment of adrenal function. The largest placebo controlled study of 437 children reported no difference in 24 hour urinary cortisol between placebo and fluticasone at doses of 100 and 200 microg per day. The non-placebo controlled study of 528 children reported significant suppression of overnight urinary cortisol levels with fluticasone at 400 compared with 200 microg per day.
conclusionsThere is insufficient data to determine the dose-response of fluticasone in children at doses >400 microg per day. The dose-response curve for fluticasone appears to plateau between 100 and 200 microg per day for efficacy. There was additional efficacy at the 400 microg per day dose in children with severe asthma; however there was evidence of adrenal suppression at this dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.